Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro

Prostate

Volumn 70, Issue 3, 2010, Pages 229-238

  Sato, Shinya ^a   Takahashi, Satoru ^a   Asamoto, Makoto ^a   Naiki, Taku ^a   Naiki Ito, Aya ^a   Asai, Kiyofumi ^a   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Bone metastasis; Bone microenvironment; Osteoclast; Prostate cancer; Tranilast

Indexed keywords

TRANILAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG MEGADOSE; FISCHER 344 RAT; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SKULL; TISSUE DIFFERENTIATION; TUMOR NECROSIS; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTHRANILIC ACIDS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW CELLS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OSTEOCLASTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED F344; SKULL; UP-REGULATION;

EID: 75649106137     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21056     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
2. Qiu D, Katanoda K, Marugame T, Sobue T. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer 2009;124(2):443-448.
3. Major PP, Cook RJ, Chen BL, Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005;2(4):234-240.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12 (20 Pt 2):6243s-6249s.
5. Brescia FJ, Portenoy RK, Ryan M, Krasnoff L, Gray G. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992;10(1):149-155.
6. Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24(34):5408-5413.
7. Speight JL, Roach M III. Advances in the treatment of localized prostate cancer: The role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol 2007;25(8):987-995.
8. Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 2003;22(42):6524-6536.
9. Tuma RS. Mechanisms of metastasis: Theories focus on microenvironment, host factors, genes. J Natl Cancer Inst 2008;100(24): 1752-1754.
10. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80(Suppl 8):1546-1556.
11. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350(16):1655-1664.
12. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, Ito N. Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,20-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res 1991;51(4):1264-1269.
13. Kato KTS, Mori S, Futakuchi M, Cui L, Ito N, Shirai T. Establishment of transplantable rat prostate carcinomas from primary lesions induced by 3, 2′-dimethyl-4-aminobiphenyl and testosterone. J Toxicol Pathol 1998;11:27-32.
14. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7(5):485-496.
15. Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 2008;99(2):316-323.
16. AzumaH, Banno K, Yoshimura T. Pharmacological properties of N-(30,40-dimethoxycinnamoyl) anthranilic acid (N-50), a new anti-atopic agent. Br J Pharmacol 1976;58(4):483-488.
17. Isaji M, Nakajoh M, Naito J. Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5′) in granulation tissue. Biochem Pharmacol 1987;36(4): 469-474.
18. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995;118(2):213-221.
19. Isaji M, Miyata H, Ajisawa Y, Takehana Y, Yoshimura N. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol 1997;122(6):1061-1066.
20. Isaji M, Aruga N, Naito J, Miyata H. Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro. Life Sci 1994;55(15):PL287-PL292.
21. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 1992;60(2):91-96.
22. Yashiro M, Chung YS, Sowa M. Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 1997;17(2A):895-900.
23. Murahashi K, Yashiro M, Inoue T, Nishimura S, Matsuoka T, Sawada T, Sowa M, Hirakawa-Ys Chung K. Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 1998;13(6):1235-1240.
24. Hiroi M, Onda M, Uchida E, Aimoto T. Anti-tumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer. J Nippon Med Sch 2002;69(3): 224-234.
25. Nie L, Oishi Y, Doi I, Shibata H, Kojima I. Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel. Cell Calcium 1997;22(2):75-82.
26. Yatsunami J, Aoki S, Fukuno Y, Kikuchi Y, Kawashima M, Hayashi SI. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol 2000;17(6):1151-1156.
27. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness ofhumanmalignant glioma cells. Int J Cancer 2001;93(1):53-61.
28. Noguchi N, Kawashiri S, Tanaka A, Kato K, Nakaya H. Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol 2003;39(3):240-247.
29. Nakanishi H, Takeuchi S, Kato K, Shimizu S, Kobayashi K, Tatematsu M, Shirai T. Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2′-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res 1996;87(12):1218-1226.
30. Fukuyama J, Ichikawa K, Miyazawa K, Hamano S, Shibata N, Ujiie A. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol 1996;70(4):321-327.
31. Kusama H, Kikuchi S, Tazawa S, Katsuno K, Baba Y, Zhai YL, Nikaido T, Fujii S. Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1. Atherosclerosis 1999;143(2):307-313.
32. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK, Labhasetwar V. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 2008;5(5): 849-862.
33. Beningo KA, Dembo M, Wang YL. Responses of fibroblasts to anchorage of dorsal extracellular matrix receptors. Proc Natl Acad Sci USA 2004;101(52):18024-18029.
34. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4(4):359-365.
35. Ko SC, Chapple KS, Hawcroft G, Coletta PL, Markham AF, Hull MA. Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene 2002;21(47):7175-7186.
36. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007;83(1):71-76.
37. Lechner S, Muller-Ladner U, Neumann E, Spottl T, Schlottmann K, Ruschoff J, Scholmerich J, Kullmann F. Thioredoxin reductase 1 expression in colon cancer: Discrepancy between in vitro and in vivo findings. Lab Invest 2003;83(9):1321-1331.
38. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008;23(1):1-9.
39. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007; 7(6):591-604.
40. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007;28(7):1379-1386.
41. Vene R, Larghero P, Arena G, Sporn MB, Albini A, Tosetti F. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res 2008;68(17):6987-6996.
42. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/ Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002; 277(34):30935-30941.